EUVIMEDEUVIMED entdecken
Crossref

Evodiamine Enhances Chemosensitivity in Colorectal Cancer by Targeting Ribonucleotide Reductase M2

An Chen, Jiaming He, Qiang Wei, Yuanyuan Wan, Yunying Li, Jing Ma, Jianhua Ran, Jing Li iD, Dilong Chen

Journal of Biochemical and Molecular Toxicology · 2025

DOI: 10.1002/jbt.70541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von An Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ribonucleoside Diphosphate Reductase, Drug Resistance, Neoplasm, Quinazolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Funding for this study was provided by the Science and Technology Research Program of Chongqing Municipal Education Commission (No. KJZD-M202202701, to Dilong….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, chemotherapy in colorectal cancer (CRC) often leads to the development of drug resistance and poor prognosis. Prior research has shown that Evodiamine (Evo) exhibits antitumor properties; however, it has not been well studied in reversing tumor multidrug resistance (MDR). Therefore, this study's main objective is to explore Evo's capacity to overcome the resistance exhibited by colorectal cancer cells towards 5‐fluorouracil (5‐FU) and uncover the molecular mechanisms that underlie this phenomenon. The impact of Evo/5‐FU on cellular viability of colorectal cancer multidrug‐resistance (MDR) cell lines was detected by CCK8 assay, and Evo on the cell cycle as well as apoptosis of multidrug‐resistant (MDR) cells, both when Evo is administered alone and in combination with 5‐FU. Based on the RNA‐seq results, the possible targets of Evo were screened, the target genes were overexpressed and silenced, RT‐qPCR validated the mRNA expression, Western blot validated protein expression, and the associated phenotypic experiments were verified. The synergistic effect of Evo on 5‐FU was investigated using a colorectal cancer xenograft tumor model. The outcomes of in vivo and in vitro experiments demonstrated that low concentrations of Evo could markedly augment the growth inhibitory impact of 5‐FU on CRC cells compared to the group treated with 5‐FU alone. The mechanism potentially involves Evo targeting RRM2 to modulate the NF‐κB and JAK2/STAT3 pathways, thereby augmenting chemotherapeutic drug‐induced apoptosis. The findings suggest that Evo effectively reversed the multidrug resistance of HCT8/5‐FU cells in vitro and in vivo by targeting RRM2. The study also offers novel evidence to support further exploration of the potential anticancer properties of Evo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsRibonucleoside Diphosphate ReductaseDrug Resistance, NeoplasmQuinazolinesNeoplasm ProteinsHumansFluorouracilAnimalsMiceXenograft Model Antitumor AssaysApoptosisMice, NudeCell Line, TumorDrug SynergismDrug Resistance, MultipleMice, Inbred BALB C

Stichwörter der Autor:innen

EvodiamineRRM2chemoresistancecolon cancer

Substanzen

evodiamineFluorouracilribonucleotide reductase M2Ribonucleoside Diphosphate ReductaseQuinazolinesNeoplasm Proteins

Autor:innen und Institutionen

  • Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing, China.
  • Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Neuroscience Research Center, Chongqing Medical University, Chongqing, China.
  • Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing Three Gorges Medical College, Chongqing, China.

ORCID-Profile: Jing Li

Förderung

  • Funding for this study was provided by the Science and Technology Research Program of Chongqing Municipal Education Commission (No. KJZD-M202202701, to Dilong…

Zitieren

APA

Chen, A., He, J., Wei, Q., Wan, Y., Li, Y., Ma, J., Ran, J., Li, J., & Chen, D. (2025). Evodiamine Enhances Chemosensitivity in Colorectal Cancer by Targeting Ribonucleotide Reductase M2. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70541

Vancouver

Chen A, He J, Wei Q, Wan Y, Li Y, Ma J, et al. Evodiamine Enhances Chemosensitivity in Colorectal Cancer by Targeting Ribonucleotide Reductase M2. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70541

BibTeX
@article{Chen2025,
  author = {Chen, An and He, Jiaming and Wei, Qiang and Wan, Yuanyuan and Li, Yunying and Ma, Jing and Ran, Jianhua and Li, Jing and Chen, Dilong},
  title = {Evodiamine Enhances Chemosensitivity in Colorectal Cancer by Targeting Ribonucleotide Reductase M2},
  journal = {Journal of Biochemical and Molecular Toxicology},
  year = {2025},
  doi = {10.1002/jbt.70541}
}
Kostenlos starten →